- Home
- FBIO vs ACET Comparison
FBIO vs ACET Comparison
Compare FBIO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- ACET
- Stock Information
- Founded
- FBIO 2006
- ACET 1947
- Country
- FBIO United States
- ACET United States
- Employees
- FBIO N/A
- ACET N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- ACET Health Care
- Exchange
- FBIO Nasdaq
- ACET Nasdaq
- Market Cap
- FBIO 49.1M
- ACET 44.4M
- IPO Year
- FBIO N/A
- ACET N/A
- Fundamental
- Price
- FBIO $1.69
- ACET $0.61
- Analyst Decision
- FBIO Strong Buy
- ACET Buy
- Analyst Count
- FBIO 3
- ACET 6
- Target Price
- FBIO $21.00
- ACET $6.00
- AVG Volume (30 Days)
- FBIO 144.5K
- ACET 566.6K
- Earning Date
- FBIO 05-19-2025
- ACET 05-06-2025
- Dividend Yield
- FBIO N/A
- ACET N/A
- EPS Growth
- FBIO N/A
- ACET N/A
- EPS
- FBIO N/A
- ACET N/A
- Revenue
- FBIO $57,675,000.00
- ACET N/A
- Revenue This Year
- FBIO $63.20
- ACET N/A
- Revenue Next Year
- FBIO $66.70
- ACET N/A
- P/E Ratio
- FBIO N/A
- ACET N/A
- Revenue Growth
- FBIO N/A
- ACET N/A
- 52 Week Low
- FBIO $1.33
- ACET $0.45
- 52 Week High
- FBIO $2.89
- ACET $1.81
- Technical
- Relative Strength Index (RSI)
- FBIO 52.97
- ACET 48.77
- Support Level
- FBIO $1.67
- ACET $0.47
- Resistance Level
- FBIO $1.84
- ACET $0.70
- Average True Range (ATR)
- FBIO 0.09
- ACET 0.06
- MACD
- FBIO 0.01
- ACET 0.00
- Stochastic Oscillator
- FBIO 58.54
- ACET 61.84
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.